

# CarVin versus CarEto - A randomised phase II study of carboplatin and vinorelbine versus carboplatin and etoposide in good performance status small cell lung cancer patients presenting with adverse prognostic factors

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> Stopped	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 04/07/2011	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Ernie Marshall

**Contact details**  
Clatterbridge Centre for Oncology  
Clatterbridge Road  
Bebington  
Wirral  
United Kingdom  
CH63 4JY  
+44 0151 334 1155  
[ernie.marshall@ccotrust.nhs.uk](mailto:ernie.marshall@ccotrust.nhs.uk)

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

N0067120650

## **Study information**

**Scientific Title**

**Study objectives**

A randomised phase II study of carboplatin and vinorelbine versus carboplatin and etoposide in good performance status small cell lung cancer patients presenting with adverse prognostic factors.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Secondary study design**

Randomised controlled trial

**Study setting(s)**

Not specified

**Study type(s)**

Not Specified

**Participant information sheet**

**Health condition(s) or problem(s) studied**

Cancer: Small cell lung cancer

**Interventions**

1. Chemotherapy with carboplatin and vinorelbine
2. Chemotherapy with carboplatin and etoposide

Added July 2008: trial stopped because of poor recruitment

**Intervention Type**

Other

**Phase**

Phase II

**Primary outcome measure**

1. Toxicity
2. Tumour response

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

08/04/2002

**Completion date**

08/04/2006

**Reason abandoned (if study stopped)**

Insufficient personel

## Eligibility

**Key inclusion criteria**

1. Elderly patients >65 years with good prognosis and Eastern Cooperative Oncology Group (ECOG) p/s <2
2. Confirmed small cell lung cancer not considered eligible for aggressive multimodality therapy

**Participant type(s)**

Patient

**Age group**

Senior

**Sex**

Not Specified

**Target number of participants**

Total target recruitment = 80 patients

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

08/04/2002

**Date of final enrolment**

08/04/2006

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

Clatterbridge Centre for Oncology

Wirral

United Kingdom

CH63 4JY

## **Sponsor information**

**Organisation**

Department of Health (UK)

**Sponsor details**

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

**Sponsor type**

Government

**Website**

<http://www.doh.gov.uk>

## **Funder(s)**

**Funder type**

Government

**Funder Name**

Clatterbridge Centre for Oncology NHS Trust (UK)

## **Results and Publications**

Publication and dissemination plan

Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration